# A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

> **NCT02406742** · PHASE1,PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 47 (actual)

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell

## Interventions

- **DRUG:** CC-122
- **DRUG:** Ibrutinib
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT02406742
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-27
- **Primary completion:** 2020-07-07
- **Final completion:** 2020-07-07
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2021-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02406742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02406742, "A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02406742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*